Format

Send to:

Choose Destination
See comment in PubMed Commons below
Proc Natl Acad Sci U S A. 2014 May 27;111(21):7723-8. doi: 10.1073/pnas.1318761111. Epub 2014 May 8.

Genetic variants of Adam17 differentially regulate TGFβ signaling to modify vascular pathology in mice and humans.

Author information

  • 1Helen Diller Family Comprehensive Cancer Center (HDFCCC) and Department of Anatomy, University of California, San Francisco, CA 94158-9001;
  • 2HDFCCC Biostatistical Core Facility, University of California, San Francisco, CA 94143;
  • 3Helen Diller Family Comprehensive Cancer Center (HDFCCC) and Department of Anatomy, University of California, San Francisco, CA 94158-9001;Department of Medical Genetics, University Medical Centre, KC04.084.2, Utrecht, The Netherlands;
  • 4Department of Medical Genetics, University Medical Centre, KC04.084.2, Utrecht, The Netherlands;
  • 5French Hereditary Hemorrhagic Telangiectasia Reference Center, Department of Medical Genetics, Lyon University Hospital, 69622 Villeurbanne, France;
  • 6St. Antonius Hospital, 3430 EM, Nieuwegein, The Netherlands;
  • 7Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232; and.
  • 8Helen Diller Family Comprehensive Cancer Center (HDFCCC) and Department of Anatomy, University of California, San Francisco, CA 94158-9001;Department of Anatomy, andInstitute of Human Genetics, University of California, San Francisco, CA 94143 rakhurst@cc.ucsf.edu.

Abstract

Outcome of TGFβ1 signaling is context dependent and differs between individuals due to germ-line genetic variation. To explore innate genetic variants that determine differential outcome of reduced TGFβ1 signaling, we dissected the modifier locus Tgfbm3, on mouse chromosome 12. On a NIH/OlaHsd genetic background, the Tgfbm3b(C57) haplotype suppresses prenatal lethality of Tgfb1(-/-) embryos and enhances nuclear accumulation of mothers against decapentaplegic homolog 2 (Smad2) in embryonic cells. Amino acid polymorphisms within a disintegrin and metalloprotease 17 (Adam17) can account, at least in part, for this Tgfbm3b effect. ADAM17 is known to down-regulate Smad2 signaling by shedding the extracellular domain of TGFβRI, and we show that the C57 variant is hypomorphic for down-regulation of Smad2/3-driven transcription. Genetic variation at Tgfbm3 or pharmacological inhibition of ADAM17, modulates postnatal circulating endothelial progenitor cell (CEPC) numbers via effects on TGFβRI activity. Because CEPC numbers correlate with angiogenic potential, this suggests that variant Adam17 is an innate modifier of adult angiogenesis, acting through TGFβR1. To determine whether human ADAM17 is also polymorphic and interacts with TGFβ signaling in human vascular disease, we investigated hereditary hemorrhagic telangiectasia (HHT), which is caused by mutations in TGFβ/bone morphogenetic protein receptor genes, ENG, encoding endoglin (HHT1), or ACVRL1 encoding ALK1 (HHT2), and considered a disease of excessive abnormal angiogenesis. HHT manifests highly variable incidence and severity of clinical features, ranging from small mucocutaneous telangiectases to life-threatening visceral and cerebral arteriovenous malformations (AVMs). We show that ADAM17 SNPs associate with the presence of pulmonary AVM in HHT1 but not HHT2, indicating genetic variation in ADAM17 can potentiate a TGFβ-regulated vascular disease.

PMID:
24812125
[PubMed - indexed for MEDLINE]
PMCID:
PMC4040598
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk